Targeting Chemoprevention of Colorectal Cancer to Those Who Are Likely to Respond

In the past four decades, chemoprevention of colorectal cancer (CRC) has been the subject of many epidemiologic and intervention trials of naturally occurring or pharmacologic agents. Recently, the positioning of cyclooxygenase 2 inhibitors as a viable option in this context was a major breakthrough...

Descripción completa

Detalles Bibliográficos
Autor principal: Stockbrugger, Reinhold W.
Formato: Texto
Lenguaje:English
Publicado: Current Science Inc. 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817803/
https://www.ncbi.nlm.nih.gov/pubmed/20157367
http://dx.doi.org/10.1007/s11888-009-0041-6
_version_ 1782177245063806976
author Stockbrugger, Reinhold W.
author_facet Stockbrugger, Reinhold W.
author_sort Stockbrugger, Reinhold W.
collection PubMed
description In the past four decades, chemoprevention of colorectal cancer (CRC) has been the subject of many epidemiologic and intervention trials of naturally occurring or pharmacologic agents. Recently, the positioning of cyclooxygenase 2 inhibitors as a viable option in this context was a major breakthrough; however, it was hampered by adverse cardiovascular events. This review questions whether chemopreventive measures for CRC are ready to be used in mass or individual applications, standing alone or in combination with other CRC-preventive measures. It also discusses steps that may be undertaken to explore this field further.
format Text
id pubmed-2817803
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Current Science Inc.
record_format MEDLINE/PubMed
spelling pubmed-28178032010-02-13 Targeting Chemoprevention of Colorectal Cancer to Those Who Are Likely to Respond Stockbrugger, Reinhold W. Curr Colorectal Cancer Rep Article In the past four decades, chemoprevention of colorectal cancer (CRC) has been the subject of many epidemiologic and intervention trials of naturally occurring or pharmacologic agents. Recently, the positioning of cyclooxygenase 2 inhibitors as a viable option in this context was a major breakthrough; however, it was hampered by adverse cardiovascular events. This review questions whether chemopreventive measures for CRC are ready to be used in mass or individual applications, standing alone or in combination with other CRC-preventive measures. It also discusses steps that may be undertaken to explore this field further. Current Science Inc. 2010-01-09 2010 /pmc/articles/PMC2817803/ /pubmed/20157367 http://dx.doi.org/10.1007/s11888-009-0041-6 Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
Stockbrugger, Reinhold W.
Targeting Chemoprevention of Colorectal Cancer to Those Who Are Likely to Respond
title Targeting Chemoprevention of Colorectal Cancer to Those Who Are Likely to Respond
title_full Targeting Chemoprevention of Colorectal Cancer to Those Who Are Likely to Respond
title_fullStr Targeting Chemoprevention of Colorectal Cancer to Those Who Are Likely to Respond
title_full_unstemmed Targeting Chemoprevention of Colorectal Cancer to Those Who Are Likely to Respond
title_short Targeting Chemoprevention of Colorectal Cancer to Those Who Are Likely to Respond
title_sort targeting chemoprevention of colorectal cancer to those who are likely to respond
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817803/
https://www.ncbi.nlm.nih.gov/pubmed/20157367
http://dx.doi.org/10.1007/s11888-009-0041-6
work_keys_str_mv AT stockbruggerreinholdw targetingchemopreventionofcolorectalcancertothosewhoarelikelytorespond

Ejemplares similares